United States· US:49502-450_e63f53ae-04f8-4bbc-afa1-c62078f09855
CIMDUO
A lamivudine and tenofovir disoproxil product containing lamivudine; tenofovir disoproxil fumarate, registered in United States by Viatris Specialty LLC. The same ATC class is registered in 2 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Lamivudine and tenofovir disoproxil is registered in 2 of 19 countries.
Countries holding a registration under ATC J05AR12 (lamivudine and tenofovir disoproxil), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 1 of them publish a price we can compare per daily dose
Lamivudine and tenofovir disoproxil · ATC J05AR12
2 / 19 countries
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
- Manufacturer
- Viatris Specialty LLC
- Country
- United States (US)
- ATC code
- J05AR12
- ATC class
- Lamivudine and tenofovir disoproxil
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1149502450931 BOTTLE, PLASTIC in 1 CARTON (49502-450-93) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
- ndc1149502-450-93
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lamivudine and tenofovir disoproxil in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5d476ea8-e433-4b4a-a2a0-1ebd7ad4c186 GET /v1/drugs/5d476ea8-e433-4b4a-a2a0-1ebd7ad4c186?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "300; 300",
"substance": "LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE",
"productndc": "49502-450",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1; mg/1",
"application_number": "NDA022141",
"marketing_category": "NDA"
}See everything about lamivudine and tenofovir disoproxil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.